Otonomy's resurrected ear drug is now dead again — and investors aren't hanging around
More than three years after it was raised from the dead, Otonomy’s lead drug appears headed to the scrap heap for good.
The drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
